LONG-TERM SAFETY OF OZANIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (UC) AND RELAPSING MULTIPLE SCLEROSIS (RMS) STUDIES

Silvio Danese  1     Douglas C. Wolf  2     OLGA ALEKSEEVA  3     Lorna Charles  4     Sonia Afsari  4     AnnKatrin Petersen  4     James K. Sheffield  4     Hongjuan Li  4     Diego Silva  4     Fred Lublin  5     Bruce A. C. Cree  6     Jeffrey Cohen  7     David T. Rubin  8    
1 Inflammatory Bowel Diseases Center, Humanitas Clinical and Research Center IRCCS and Hunimed, Milan, Italy
2 Center for Crohn’s Disease & Ulcerative Colitis, Atlanta Gastroenterology Associates, Atlanta, United States
3 Nizhni Novgorod Regional Clinical Hospital, Nizhny, Novgorod, Russia
4 Bristol Myers Squibb Company, Princeton, United States
5 Icahn School of Medicine at Mount Sinai, New York, United States
6 Weill Institute for Neurosciences, University of California San Francisco, San Francisco, United States
7 Mellen Center for Multiple Sclerosis Treatment and Research, Cleveland, United States
8 University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing